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Summary
Background In the Global Burden of Disease Study 2013 (GBD 2013), knowledge about health and its determinants has 
been integrated into a comparable framework to inform health policy. Outputs of this analysis are relevant to current 
policy questions in England and elsewhere, particularly on health inequalities. We use GBD 2013 data on mortality and 
causes of death, and disease and injury incidence and prevalence to analyse the burden of disease and injury in England 
as a whole, in English regions, and within each English region by deprivation quintile. We also assess disease and injury 
burden in England attributable to potentially preventable risk factors. England and the English regions are compared with 
the remaining constituent countries of the UK and with comparable countries in the European Union (EU) and beyond.
Methods We extracted data from the GBD 2013 to compare mortality, causes of death, years of life lost (YLLs), years 
lived with a disability (YLDs), and disability-adjusted life-years (DALYs) in England, the UK, and 18 other countries (the 
ﬁ rst 15 EU members [apart from the UK] and Australia, Canada, Norway, and the USA [EU15+]). We extended elements 
of the analysis to English regions, and subregional areas deﬁ ned by deprivation quintile (deprivation areas). We used 
data split by the nine English regions (corresponding to the European boundaries of the Nomenclature for Territorial 
Statistics level 1 [NUTS 1] regions), and by quintile groups within each English region according to deprivation, thereby 
making 45 regional deprivation areas. Deprivation quintiles were deﬁ ned by area of residence ranked at national level 
by Index of Multiple Deprivation score, 2010. Burden due to various risk factors is described for England using new 
GBD methodology to estimate independent and overlapping attributable risk for ﬁ ve tiers of behavioural, metabolic, 
and environmental risk factors. We present results for 306 causes and 2337 sequelae, and 79 risks or risk clusters.
Findings Between 1990 and 2013, life expectancy from birth in England increased by 5·4 years (95% uncertainty interval 
5·0–5·8) from 75·9 years (75·9–76·0) to 81·3 years (80·9–81·7); gains were greater for men than for women. Rates of 
age-standardised YLLs reduced by 41·1% (38·3–43·6), whereas DALYs were reduced by 23·8% (20·9–27·1), and YLDs 
by 1·4% (0·1–2·8). For these measures, England ranked better than the UK and the EU15+ means. Between 1990 and 
2013, the range in life expectancy among 45 regional deprivation areas remained 8·2 years for men and decreased 
from 7·2 years in 1990 to 6·9 years in 2013 for women. In 2013, the leading cause of YLLs was ischaemic heart disease, 
and the leading cause of DALYs was low back and neck pain. Known risk factors accounted for 39·6% (37·7–41·7) of 
DALYs; leading behavioural risk factors were suboptimal diet (10·8% [9·1–12·7]) and tobacco (10·7% [9·4–12·0]).
Interpretation Health in England is improving although substantial opportunities exist for further reductions in the 
burden of preventable disease. The gap in mortality rates between men and women has reduced, but marked health 
inequalities between the least deprived and most deprived areas remain. Declines in mortality have not been matched 
by similar declines in morbidity, resulting in people living longer with diseases. Health policies must therefore 
address the causes of ill health as well as those of premature mortality. Systematic action locally and nationally is 
needed to reduce risk exposures, support healthy behaviours, alleviate the severity of chronic disabling disorders, and 
mitigate the eﬀ ects of socioeconomic deprivation.
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Introduction
The Global Burden of Disease (GBD) project is a 
worldwide exercise to integrate the widest possible range 
of reliable knowledge about health and its determinants 
into a universal health framework. Outputs allow 
meaning ful comparisons between countries and over 
time, and quantify the contributions of diﬀ erent diseases 
and risk factors to overall burden.
Investigators of a previous GBD study1 used data from 
2010 to compare the UK with a group of other countries. 
The new analysis reported here uses data from 1990 
through 2013 and focuses on England. Responsibility for 
health and public health has been devolved to the 
constituent countries of the UK (England, Scotland, Wales, 
and Northern Ireland) since 1998,2 so this geographical 
level of analysis is most meaningful. We compare England 
and the English regions with the remaining constituent 
countries of the UK, and with comparable countries in the 
European Union (EU) and beyond. This study comes at a 
time when both national and local health-policy makers 
are reviewing and reassessing priorities for action in the 
light of ﬁ nancial pressures. The potential for prevention 
and public health to secure improved population health 
and reduce demand on England’s National Health Service 
(NHS) has also received further attention recently.3
The Global Burden of Diseases, Injuries, and Risk Factors 
Study 2013 (GBD 2013) provides both improve ments in 
data and advances in methodology compared with previous 
versions of the GBD.4–7 These advances include a greatly 
improved approach to identiﬁ cation of the contribution of 
various risk factors and combinations of risks, as explained 
in the Methods and reported in detail elsewhere,6 as well as 
updates to many data sources.
The subnational analysis reported here, based on 
English regions and areas within them that have diﬀ ering 
levels of deprivation, makes it possible to map disease 
burden according to socioeconomic deter minants of 
health. This report therefore not only uses an improved 
approach but also extends the scope of earlier work and 
increases its relevance to policy makers in several ways.
Methods
Overview
Here we use data from the GBD 2013 study of causes of 
death, disease, and injury incidence and prevalence as 
well as years lived with disability (YLDs) to analyse the 
burden of diseases and injuries in England by English 
region and, within each English region by deprivation 
quintile (deﬁ ned nationally). The methods employed in 
the GBD 2013, including the systematic approach to 
collating cause of death from diﬀ erent countries, the 
mapping across diﬀ erent revisions and national variants 
of the International Classiﬁ cation of Diseases and 
Injuries (ICD), redistribution of deaths assigned to 
so-called garbage codes, and the cause of death 
modelling approach used for each cause, have been 
described in detail elsewhere.4 The GBD 2013 
Collaborators5 describe the data and methods used to 
Research in context
Evidence before this study
Responsibility for health and public health has been devolved to 
the constituent countries of the UK since 1998, but no single 
accessible source describing disease burden by cause in England 
exists. A published estimate of burden of disease for the UK, 
using GBD 2010 data and methodology, has been widely used 
by policy makers but has limitations and needs updating. 
Routine mortality statistics show progressive improvements in 
life expectancy, but inequalities persist between countries in the 
UK and regions within England. Routine measures of morbidity 
are not reported in a way that allow direct comparisons of 
burden between causes at a national or regional level. 
Attributable risks have been calculated for some causes (eg, 
smoking and air pollution) and for some disorders (eg, cancers) 
but are not available in a comprehensive framework covering 
multiple risks and diseases. Relevant literature reviews were 
undertaken to inform components of the GBD analysis in 
particular on the relation between risk factors and outcomes.
Added value of this study
The GBD 2013 analysis of causes of death, disease, and injury 
incidence and prevalence, YLDs, and risk factors is a major 
update and improvement in the evidence base underlying the 
quantiﬁ cation of comparable disease and risk factor estimates 
compared with the most recent GBD analyses in 2010. For the 
ﬁ rst time, GBD results for England are quantiﬁ ed at the national 
and subnational level (at the level of nine English regions) and 
by IMD-2010 deprivation quintile using a range of routine and 
published data sources.
Implications
Quantiﬁ cation of the continuing burden of preventable ill 
health in England more than justiﬁ es recent calls for a “radical 
upgrade in prevention and public health”. A huge opportunity 
exists for preventive public health: if levels of health in the 
worst performing regions in England matched the best 
performing ones, England would have one of the lowest 
burdens of disease of any advanced industrialised country. 
The scale of the increasing level of disability suggests the need 
for new, more integrated models of care spanning health and 
social services that respond to the speciﬁ c needs and 
circumstances of individual patients. Inequalities in health are 
greater within English regions than between them and are 
therefore largely related to deprivation, not geography. The 
causes of inequalities need to be addressed wherever they 
occur. The importance of prevention argues for investment in 
robust, standardised comparative assessments of the 
cost-eﬀ ectiveness of diﬀ erent public health policies to aid 
decision making, akin to those used in England for health 
technologies. 
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estimate incidence, prevalence, and YLDs for 306 causes 
and 2337 sequelae from 1990 to 2013, a substantial 
increase from 220 causes and 1160 sequelae in the GBD 
2010 analysis.1 This GBD 2013 paper includes a 
description of the systematic reviews of the published 
literature, identiﬁ cation of unpublished data sources, 
eﬀ orts to map data to a consistent set of case deﬁ nitions, 
and the general approach to Bayesian meta-regression 
using DisMod-MR 2.0, which allows the estimation of 
incidence, prevalence, remission, excess mortality, 
and cause-speciﬁ c mortality rates that are internally 
consistent. Details of the method, the likelihood used in 
estimation, and the source code have been published 
elsewhere.8,9 The analysis of risk factor-attributable 
burden uses the GBD 2013 framework and results.6 
Sampling and non-sampling error as well as model 
uncertainty is propagated by estimating all steps in the 
calculations 1000 times. 95% uncertainty intervals (UIs) 
are presented by the 2·5 and 97·5 centile values.
Another new feature of the GBD 2013 study is the 
systematic aggregation of the burden attributed to 
ﬁ ve tiers of risk factors: the ﬁ rst tier is all GBD risks 
combined; the second tier consists of three large 
categories of metabolic, behavioural, and environmental 
and occupational risks; the third tier contains single 
risks, such as high blood pressure, and risk clusters, 
such as child and maternal under-nutrition or air 
pollution; the fourth tier includes single risks within 
such clusters, such as vitamin A deﬁ ciency or household 
air pollution; and the ﬁ fth tier is for individual 
occupational carcinogens or the division of childhood 
underweight into stunting, underweight, and wasting. At 
each level of the hierarchy, a decision is made whether 
the combined eﬀ ects are independent and can be added, 
whether they are joint eﬀ ects best represented by 
multiplication, or whether they share common pathways 
for which mediation needs to be taken into account. For 
each aggregation, the proportion of the eﬀ ect shared with 
another risk or combination of risks can thus be made 
explicit, using modiﬁ ed Venn diagrams that show the 
overlaps between metabolic, behavioural, and environ-
mental and occupational risks.
Here we focus on speciﬁ c issues related to the analysis 
of causes of death, injury incidence and prevalence, and 
risk factor prevalence in England, the nine English 
regions, and 45 subregional areas deﬁ ned by deprivation 
quintile (deprivation areas).
Division of England into English regions and 
deprivation areas
Estimates of disease burden have been created for 
the nine English regions, as deﬁ ned by the former 
government oﬃ  ce regions in England, and correspond 
to the European boundaries of the Nomenclature for 
Territorial Statistics level 1 (NUTS 1) regions. In a 
further reﬁ nement, all English lower super output 
areas, relatively homogeneous areas containing about 
1600 people on average,10 were ranked nationally using 
the Index of Multiple Deprivation (IMD-2010) and 
allocated to quintiles. The IMD-2010 is a composite 
measure estimated at a small geographical area and 
includes seven domains: income, employment, health 
and disability, education, skills and training, barriers to 
housing and services, living environment, and crime.11 
The health and disability domain of the IMD-2010 
contributes 13·5% to the score and encompasses four 
measures: years of potential life lost, comparative illness 
and disability ratio, rate of emergency admissions to 
hospital, and proportion of adults younger than 60 years 
who have mood or anxiety disorders. Although inevitably 
partially correlated with health, exclusion of the health 
component from an earlier version of the IMD has been 
shown to make little diﬀ erence to ranking of areas by 
deprivation in practice.12 The lower super output areas in 
each quintile were then reallocated to their region, 
thereby dividing each of the nine English regions into 
ﬁ ve deprivation groups, or 45 regional deprivation areas 
in total. As the lower super output areas at each level of 
deprivation are unevenly distributed among the English 
regions, there will be a greater share of the regional 
population living in the most deprived and least deprived 
(nationally) areas in each English region. Thus, the 
proportion of the population in the most deprived group 
ranges from 7·3% in South East England to 32·8% in 
North West England. For the least deprived group, this 
proportion ranges from 7·9% in Greater London to 
34·8% in South East England. The complete breakdown 
of these proportions is provided in the appendix (p 4). 
Within each English region, the most deprived area is 
referred to as deprivation level 1, and the least deprived 
area as deprivation level 5.
Mortality data for England from 1990 to 2012, available 
from the Oﬃ  ce for National Statistics, were split into 
regional and deprivation groups based on the postcode 
of residence. Where a postcode for the deceased had not 
been provided, these deaths were discarded from the 
analysis of England mortality because no residence in 
England was assumed. These records make up less than 
0·3% of all mortality records. Each death was assigned 
to a lower super output area, deprivation group, and 
English region on the basis of the person’s postcode. 
GBD estimation of disease prevalence and incidence 
also makes use of social, cultural, economic, and 
environmental covariates; some covariate and morbidity 
data were available at the level of English region. The 
source data for England used at each level are provided 
in the appendix p 5; regional level covariates that have 
been included are listed in the appendix p 44.
Analysis of cause of death by English region and 
deprivation area
As outlined in the GBD 2013 report about global 
mortality and cause of death,4 vital registration data 
covering the years 1980 to 2012 were analysed at the 
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regional level. Registration of deaths that happen in 
England is a legal requirement, and because registration 
is necessary before disposal of the body, mortality data 
are assumed to be complete.1,13,14 We reclassiﬁ ed causes 
of death for deaths assigned to causes that cannot or 
should not be an underlying cause of death, so-called 
garbage codes.15,16 Standard GBD 2013 redistribution of 
garbage-code algorithms was applied.17 Although data 
were available for all years between 1980 and 2012, to 
deal with stochastic variation at the regional level, while 
following the GBD 2013 methods, we modelled causes 
of death using cause of death ensemble modelling 
(CODEm).4,18 CODEm has been used extensively to 
model causes of death; an ensemble model is developed 
by testing the performance of a wide array of models 
(mixed eﬀ ects or space–time Gaussian process 
regression), diﬀ erent measures of mortality (rates or 
cause fractions) and varying combinations of covariates 
(drawing on a database created for GBD of more than 
200 diverse characteristics for countries over time, such 
as gross domestic product, level of education, dietary 
factors, use of health-service, and environmental 
statistics), and by selecting the models with best 
out-of-sample performance. For example, GBD suicide 
estimates for the UK are lower than those produced by 
the Oﬃ  ce for National Statistics by almost a quarter. The 
Oﬃ  ce for National Statistics estimates include all deaths 
coded as suicide (ICD-10 X60–X84) and deaths coded as 
due to injury and poisoning of undetermined intent 
(ICD Y10–34),19 whereas GBD uses a redistribution 
approach, coding only a proportion of undetermined 
intent deaths as suicide.
The GBD places disease categories within a four-level 
cause hierarchy. The ﬁ rst level divides causes into 
communicable diseases, non-communicable diseases, 
and injuries; the second level consists of major disease or 
injury groups, such as cardiovascular diseases or 
transport injuries; the third level (at which most results 
are reported) further subdivides causes into disease or 
injury types, such as cerebrovascular disease or road 
injuries; and a ﬁ nal fourth level subdivides those disease 
types where appropriate. Further details can be found in 
the supplementary appendix of the GBD 2013 Mortality 
and Cause of Death report.4
Tabulations of deaths by cause were generated by 
deprivation area within each English region. Where the 
causes of deaths were identiﬁ ed as garbage codes, these 
were reclassiﬁ ed using the GBD 2013 algorithms. Owing 
to small sample size in some age–sex–cause groups, we 
sought to smooth stochastic variation over time. To 
estimate causes of death by age, sex, and year for a 
deprivation area within each English region, we ﬁ rst 
computed the fraction of deaths for a cause–sex–age–
year in each deprivation area. To minimise the eﬀ ect of 
stochastic ﬂ uctuations on the results, we used a 3-year 
moving average for age groups over 15 years, and a 5-year 
moving average for age groups under 15 years. We chose 
a longer time period for the moving average for childhood 
age groups because these data are most prone to 
ﬂ uctuations due to small numbers of annual deaths. 
Moving-average deprivation-area fractions within a 
cause–age–sex–year group were rescaled so that the sum 
of cause fractions equalled 100%. These deprivation-area 
fractions were multiplied by the regional level ﬁ nal 
estimates of death counts for an age–sex–year group for a 
given cause to generate estimates of ﬁ nal death counts 
for each deprivation area. Death counts were divided by 
deprivation area population to generate deprivation-level 
cause–age–sex–year rates.
Disease and injury incidence, prevalence, and YLDs by 
English region and deprivation area
A list of sources used for the analysis of non-fatal health 
outcomes in England organised by disease is provided in 
the appendix (p 5). These sources include studies 
extracted from the published literature through the GBD 
systematic reviews as well as extractions from surveys, 
such as the Health Survey for England,20 and 
administrative sources, such as NHS hospital discharge 
data. We also used new data from the UK-based Cognitive 
Function and Ageing Studies.21 Most disease sequelae 
have been modelled in GBD 2013 using a Bayesian 
meta-regression method, DisMod-MR 2.0, in which each 
English region has been analysed as a distinct geographic 
unit. A prior for the Bayesian meta-regression is 
calculated for each English region using the data for all 
countries in western Europe, with random eﬀ ects on 
countries and English regions and ﬁ xed eﬀ ects that vary 
by the disease being modelled.
To analyse injuries, we made use of both the external 
cause of injury and the nature of injury. As detailed 
elsewhere,5 we used survey and hospital activity data to 
estimate incidence of injuries for which hospital 
admission was necessary and injuries for which hospital 
admission was not necessary. Hospital data dual-coded 
to nature of injury and external cause of injury were 
used to estimate the fraction of each injury with 
diﬀ erent types of disabling sequelae. Cohort studies 
from four countries were used to estimate the probability 
of long-term disability for each type of injury.6,22,23 
DisMod-MR 2.0 was used to estimate the prevalence of 
injury in each birth cohort on the basis of long-term 
disability arising from past incidence. Given the absence 
of data on injury incidence before 1980, we assumed 
that age-speciﬁ c incidence in cohorts before 1980 was 
equal to the rate in 1980.
Following the GBD 2013 methods, prevalence of 
individuals in each sequela was multiplied by the 
disability weight for the corresponding health state to 
calculate YLDs for the particular sequela. The sum of 
all the YLDs for relevant sequelae is the overall YLD for 
each disease. We based disability weights on the 
responses by the general public to questions about 
which health state of randomly chosen pairs represents 
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a higher state of health. GBD 2013 disability weights 
were based on the pooled analysis of 60 890 responses 
from household surveys done in a wide range of 
settings (USA, Peru, Tanzania, Bangladesh, Indonesia, 
Italy, Hungary, Sweden, and the Netherlands, and an 
open access internet survey) to allow them to be 
generalised to the global population.22 We analysed the 
disability weight surveys to generate 235 health state 
weights on a scale of 0·0 (perfect health) to 1·0 (like 
death). Each of the 2337 sequelae in the study are 
mapped to a particular health state and its associated 
disability weight. Results showed little variation by 
country of survey or level of education of respondents, 
justifying the use of a single set of disability weights for 
all countries and time periods.
YLDs for deprivation areas have been estimated from 
regional level results. For causes where substantial 
mortality exists, we have assumed that the pattern of 
disease prevalence mirrors the pattern of mortality in an 
age–sex group. For causes where there is minimal 
mortality and no available data, we have assumed that 
YLD rates for an age–sex group are constant across 
deprivation levels in an English region. The threshold 
used to deﬁ ne minimal mortality is if the ratio of years 
of life lost (YLLs) to YLDs was less than 0·15.
Age standardisation, multiple-decrement life tables, 
and benchmarking years of life lost
The GBD 2013 global age-standard population was used 
to compute age-standardised rates.4
We used multiple-decrement life tables to compute the 
contribution of changes in cause-speciﬁ c mortality to 
changes in life expectancy for each English region and 
deprivation area from 1990 to 2013.24,25
We computed YLLs by multiplying numbers of deaths 
from each cause in each age group by the reference life 
expectancy at the average age of death for those who die 
in the age group, as in the GBD 2010.9,13,16,26,27 The reference 
life expectancy at birth is 86·02 years and is based on the 
lowest age-speciﬁ c death rates observed in all countries 
with populations greater than 5 million in 2010. We 
compared English regions and England as a whole with 
18 other comparator nations (the ﬁ rst 15 members of the 
EU [apart from the UK], Australia, Canada, Norway, and 
the USA; EU15+). This set of countries has been used in 
previous benchmarking analyses for the UK.1
To describe the proportional share of the variation for 
deprivation group and English region, ANOVA was carried 
out at regional level and, for each deprivation area, within 
English regions. We did the analysis separately for each 
outcome measure (death, YLLs, YLDs, disability-adjusted 
Death YLLs YLDs DALYs Life expectancy
Deprivation Region Deprivation Region Deprivation Region Deprivation Region Deprivation Region
Men
1990 86·8%
(65·3–96·9)
7·8%
(1·2–24·1)
92·5%
(78·2–98·5)
5·2%
(0·9–17·6)
86·4%
(64·6–96·9)
8·5%
(1·3–25·9)
96·3%
(88·4–99·3)
2·2%
(0·3–8·1)
94·2%
(82·3–98·8)
4·3%
(0·7–13·9)
1995 86·0%
(64·6–96·6)
6·0%
(0·8–19·5)
93·2%
(80·7–98·6)
3·4%
(0·5–11·9)
86·3%
(66·3–96·6)
7·0%
(1·0–20·8)
96·8%
(90·7–99·3)
0·9%
(0·1–3·7)
93·7%
(82·0–98·6)
3·0%
(0·4–10·2)
2000 89·7%
(73·7–97·6)
4·6%
(0·6–14·0)
94·5%
(84·3–98·8)
3·2%
(0·5–11·3)
89·5%
(70·6–97·6)
6·8%
(1·1–21·2)
97·7%
(92·6–99·5)
0·6%
(0·0–3·2)
95·0%
(85·3–98·9)
2·4%
(0·3–8·3)
2005 92·3%
(78·6–98·4)
4·8%
(0·7–16·1)
93·7%
(81·7–98·6)
4·1%
(0·7–13·2)
85·6%
(62·9–96·3)
7·6%
(1·1–24·9)
96·2%
(89·0–99·1)
1·5%
(0·1–5·3)
94·6%
(83·8–98·9)
3·5%
(0·5–11·5)
2010 92·1%
(78·2–98·4)
4·5%
(0·6–14·9)
92·6%
(78·8–98·3)
4·1%
(0·6–13·3)
84·0%
(59·3–96·0)
9·9%
(1·9–29·0)
95·5%
(86·7–99·1)
1·2%
(0·1–5·6)
94·4%
(83·4–98·8)
3·3%
(0·5–11·1)
2013 92·8%
(80·9–98·5)
3·2%
(0·4–10·4)
91·1%
(75·1–98·3)
5·1%
(0·7–16·0)
86·5%
(63·3–97·0)
8·5%
(1·4–24·7)
94·3%
(84·7–98·8)
2·0%
(0·2–7·3)
94·6%
(84·5–98·8)
2·5%
(0·3–8·6)
Women
1990 80·1%
(54·4–94·6)
9·8%
(1·6–31·3)
86·4%
(64·1–96·9)
6·8%
(1·1–22·8)
86·2%
(63·3–96·7)
5·6%
(0·8–19·1)
89·2%
(73·3–97·5)
4·5%
(0·6–15·6)
86·0%
(64·3–96·6)
6·7%
(1·0–21·4)
1995 82·1%
(56·6–95·6)
6·9%
(0·9–21·6)
89·6%
(70·5–97·4)
5·2%
(0·7–17·9)
91·4%
(75·2–98·2)
4·6%
(0·6–14·8)
93·4%
(82·1–98·6)
2·6%
(0·3–8·9)
88·2%
(68·9–97·2)
4·5%
(0·5–15·2)
2000 79·1%
(53·1–94·6)
6·2%
(0·8–22·8)
85·8%
(64·1–96·6)
6·8%
(1·1–20·0)
87·4%
(67·9–97·2)
4·8%
(0·5–17·5)
90·8%
(75·8–98·0)
3·2%
(0·3–11·9)
85·0%
(61·9–96·3)
3·6%
(0·2–15·8)
2005 78·3%
(48·1–95·3)
13·0%
(2·1–35·3)
81·3%
(53·3–95·3)
12·5%
(2·0–35·5)
81·6%
(55·1–95·8)
5·6%
(0·6–22·8)
86·6%
(66·9–96·9)
6·5%
(0·9–20·9)
82·8%
(57·4–95·8)
10·5%
(1·9–29·3)
2010 80·9%
(54·3–95·0)
9·6%
(1·5–28·1)
79·1%
(50·5–94·4)
12·8%
(2·3–36·3)
70·8%
(37·7–91·9)
22·1%
(4·9–53·5)
85·6%
(64·7–96·5)
5·9%
(0·9–18·6)
84·5%
(61·2–96·2)
7·9%
(1·3–24·3)
2013 82·5%
(56·0–95·7)
7·8%
(1·2–27·4)
78·7%
(50·3–94·1)
11·7%
(2·3–32·8)
81·4%
(57·1–95·5)
7·9%
(1·0–26·3)
83·9%
(59·8–96·1)
6·4%
(0·7–22·7)
86·2%
(64·7–96·6)
5·8%
(0·8–18·8)
Data are percentage variance (95% uncertainty interval). YLLs=years of life lost. YLDs=years lived with disability. DALYs=disability-adjusted life-years. Deprivation=deprivation area. Region=English region. 
Table 1: Decomposition of variance in deaths, YLLs, YLDs, DALYs, and life expectancy for men and women, separately, into contributions from level of deprivation and English region for 
1990, 1995, 2000, 2005, 2010, and 2013
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life years [DALYs], life expectancy), and for speciﬁ c years 
(1990, 1995, 2000, 2005, 2010, 2013). Models with main 
eﬀ ects for region and deprivation, and of the interaction of 
English region and deprivation, were ﬁ tted to the data. 
Decomposition of variance was estimated using mixed-
eﬀ ects linear regression employing Gelman’s methods.28 
UIs for the decomposition of variance were based on two 
steps. First, we took 1000 draws from the standard error of 
the random eﬀ ect across English regions  and the random 
eﬀ ect across deprivation levels. Second, we computed the 
fraction of variance explained by English region and 
deprivation level based on each of these draws. Table 1 
shows the proportion of the variance due to deprivation 
and due to English region (with 95% UIs).
Role of the funding source
The GBD 2013 database development, methods improve-
ment, and global analysis is primarily funded by the Bill & 
Melinda Gates Foundation, which had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. Public Health England contributed 
to the interpretation of data, the writing of the report, and 
the decision to submit the paper for publication. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility to submit the paper.
Results
Between 1990 and 2013, life expectancy from birth in 
England increased by 5·4 years (95% UI 5·0–5·8) from 
75·9 years (75·9–76·0) to 81·3 years (80·9–81·7), and 
age-standardised death rates were reduced by 33·6% 
(31·1–36·1; appendix p 21). During the same time 
period, the relative reduction in the rate of age-
standardised YLLs was 41·1% (38·3–43·6), indicating a 
proportionately larger reduction in premature mortality 
when compared with overall mortality. In comparison, 
age-standardised rates of YLDs, which capture the 
burden of disability, decreased by only 1·4% (0·1–2·8). 
With DALYs, which combine mortality and disability, 
there was an overall reduction of 23·8% (20·9–27·1) 
between 1990 and 2013. Compared with the EU15+ 
countries, in 2013, England ranked eighth for age-
standardised death rates, seventh for YLLs, seventh for 
YLDs, and sixth for DALYs; better than the UK as a 
whole on all measures. Corresponding results for the 
constituent countries of the UK and the English regions 
are provided in the appendix (p 21).
Figure appendix 1 shows the change in life expectancy 
from 1990 to 2013 by broad cause group for men and 
women separately and for both sexes combined 
in England, the English regions, Scotland, Northern 
Ireland, Wales, and the EU15+ countries. Between 1990 
and 2013, England overall achieved one of the largest 
gains in life expectancy among men, with 6·4 gained 
years, less than Luxembourg but tying with Finland. All 
English regions except for South West England, achieved 
a gain of at least 6·0 years, equal to or greater than all 
comparator countries except Austria, Finland, Ireland, 
Germany, and Luxembourg. Among women, the increase 
in life expectancy in England overall was more modest 
Figure 1: The 25 leading GBD level 3 causes of years of life lost (YLLs) in England, both sexes combined, 1990, 2005, and 2013, with age-standardised median percent change
Ranks are based on the number of YLLs. 95% UIs for mean rank are from 1000 draws of YLLs. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.
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than for men, with 4·4 years, yet still equalled or exceeded 
that of all countries except Finland, Germany, Ireland, 
Luxembourg, and Portugal.
In 1990, the life expectancy of men in England was lower 
than in many western countries, such as Canada, France, 
Norway, the Netherlands, and Spain; however, by 2013, life 
expectancy of men in England had surpassed that of each 
of these countries, reaching 79·5 years (95% UI 
78·9–80·0). In three regions of England, South West 
England, East of England, and South East England, the life 
expectancy of men was 80 years or above, which is better 
than that in Australia and in Sweden. The main drivers for 
improvement in life expectancy in nearly all countries and 
in the English regions have been declines in cardiovascular 
disease and, to a lesser extent, cancer mortality. Decreases 
in chronic respiratory disease and road injuries have also 
been important contributors. Increased mortality from 
cirrhosis of the liver and from mental and substance use 
disorders (mostly attributed to alcohol use) made negative 
contributions to life expectancy in all the English regions 
except for Greater London and South East England.
For women, life expectancy at birth across countries 
and the English regions in 2013 ranged from 81·0 years 
(95% UI 80·3–81·7) in Scotland to 84·9 years (84·4–85·4) 
in France. Geographical patterns, however, are somewhat 
diﬀ erent from those for men, with the highest life 
expectancy for women in Spain, Italy, and France. 
Australia and South East England reached a female life 
expectancy of 84·0 years (83·5–84·5 and 83·3–84·6, 
respectively) in 2013, whereas two English regions and 
four countries have a female life expectancy at or below 
82 years, namely: North East England, North West 
England, Scotland, USA, Northern Ireland, and Denmark. 
As with men, the key drivers of increases in female life 
expectancy have been reductions in cardiovascular 
diseases and cancers. For most countries, sex diﬀ erences 
in life expectancy decreased between 1990 and 2013; in 
England, the gap closed by 2·2 years.
Figure 2: Age-standardised rates of years of life lost (YLLs) for England and the nine English regions relative to EU15 countries, Australia, Canada, Norway, the USA, Scotland, Northern 
Ireland, and Wales for both sexes combined in 2013
EU15+ countries, UK constituent countries, and English regions are ordered by the overall mean age-standardised YLL rate. To facilitate comparison, England and the nine English regions are shown in 
bold. For illustrative purposes only, UK constituent countries and the English regions have been included where they would rank if they were one of the EU15+ countries; this is not to suggest that the 
health system in a given English region is equivalent to that of any of the countries to which it is adjacent in the list. Rates are colour-coded to denote statistically signiﬁ cant diﬀ erences from the mean 
across this set of English regions and countries. Lung cancer=lung, bronchus, and trachea cancer. COPD=chronic obstructive pulmonary disease. Alzheimer’s disease=Alzheimer’s disease and other 
dementias. Other cardiovascular=other cardiovascular and circulatory diseases. Cirrhosis hepatitis C=cirrhosis of the liver secondary to hepatitis C. Brain cancer=brain and central nervous system cancer.
Significantly lower than mean
Indistinguishable from mean
Significantly higher than mean
897 510 429 299 279 306 289 294 233 154 136 124 126 210 137 177 192 93·2 111 77·3 130 88·5 99·9 106 116
883 571 487 185 337 100 302 238 201 172 79·6 86·9 37·9 213 172 381 154 115 109 166 114 45·8 71·9 124 54·4
1007 526 432 279 284 305 292 298 231 151 133 134 120 237 138 197 238 80·1 108 85·1 123 91·6 103 105 117
1348 436 500 208 230 164 330 200 492 163 112 182 47·4 195 128 187 57·8 74·6 85 87·4 133 94·2 81·2 110 118
980 522 466 294 281 298 305 297 281 153 140 132 138 225 140 208 228 103 120 85·5 134 86·6 98·7 114 152
942 619 489 288 307 210 358 215 232 158 127 100 62·9 215 164 311 93·3 122 85·9 160 123 42·3 68·2 109 113
994 522 409 276 263 127 312 233 445 154 90·1 149 82·3 230 134 352 109 60·9 118 97·7 129 56·4 67·9 111 171
1055 582 491 330 355 212 405 194 465 169 105 174 49·3 209 122 215 59·5 53·2 90·3 99·9 143 84·3 91 105 281
1085 695 592 317 230 184 326 263 432 175 205 111 82·5 109 112 317 64·9 164 101 117 139 38·9 92·1 124 159
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1437 890 686 500 305 356 363 285 481 170 138 131 182 239 157 201 156 192 117 138 146 73·3 103 112 332
1697 782 457 472 422 268 282 238 512 186 136 113 74·7 300 151 615 259 179 121 74·2 114 56 82·6 127 359
South East England
Italy
East of England
Sweden
South West England
Spain
Australia
Norway
Luxembourg
Greater London
England
East Midlands
France
Canada
UK
Netherlands
Germany
Austria
West Midlands
Ireland
Finland
Yorkshire and the Humber
Belgium
Wales
North East England
Denmark
Greece
North West England
Portugal
Northern Ireland
Scotland
USA
Isc
ha
em
ic 
he
ar
t d
ise
as
e
Lu
ng
 ca
nc
er
Ce
re
br
ov
as
cu
la
r d
ise
as
e
CO
PD
Al
zh
ei
m
er
’s 
di
se
as
e
Lo
w
er
 re
sp
ira
to
ry
 in
fe
ct
io
ns
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
s
Br
ea
st
 ca
nc
er
Se
lf-
ha
rm
Pa
nc
re
at
ic 
ca
nc
er
O
th
er
 ca
rd
io
va
sc
ul
ar
Pr
os
ta
te
 ca
nc
er
O
es
op
ha
ge
al
 ca
nc
er
Co
ng
en
ita
l a
no
m
al
ie
s
O
th
er
 n
eo
pl
as
m
s
Ro
ad
 in
ju
ry
Pr
et
er
m
 b
irt
h 
co
m
pl
ica
tio
ns
Ci
rrh
os
is 
he
pa
tit
is 
C
N
on
-H
od
gk
in
 ly
m
ph
om
a
St
om
ac
h 
ca
nc
er
Br
ai
n 
ca
nc
er
Ao
rt
ic 
an
eu
ry
sm
O
va
ria
n 
ca
nc
er
Le
uk
ae
m
ia
Dr
ug
 u
se
 d
iso
rd
er
s
Articles
2264 www.thelancet.com   Vol 386   December 5, 2015
Figure appendix 2 shows a similar analysis of changes 
in life expectancy from 1990 to 2013 by cause for the 
45 deprivation areas of England. For men, life expectancy 
in 2013 ranged from 74·9 years (95% UI 74·1–75·7) in 
North West England deprivation level 1 (most deprived) 
to 83·1 years (82·3–83·9) in East of England deprivation 
level 5 (least deprived; ﬁ gure appendix 2). The range of 
8·2 years between deprivation areas in 2013 is unchanged 
for men since 1990. For women, the equivalent ﬁ gures in 
2013 were 79·5 years (78·7–80·2) in North West England 
deprivation level 1 (most deprived) to 86·4 years 
(85·6–87·3) in East of England deprivation level 5 (least 
deprived; ﬁ gure appendix 2); the range has therefore 
decreased for women from 7·2 years to 6·9 years. 
Overall, there has been little if any improvement in 
inequality in life expectancy across regions of England: 
by 2013, people living in the most deprived areas have 
not yet reached the levels of life expectancy that less 
deprived groups had in 1990.
The ordering of the 45 deprivation areas largely follows 
deprivation level across English regions. There are a few 
crossovers such as Greater London deprivation level 1, 
which has better life expectancy than North West 
England deprivation level 2 (ﬁ gure appendix 2). Table 1 
Figure 3: Age-standardised rates of years of life lost (YLLs) for England relative to the deprivation levels in the nine English regions for both sexes combined in 2013
To facilitate comparison, England is shown in bold. Lung cancer=lung, bronchus, and trachea cancer. COPD=chronic obstructive pulmonary disease. Alzheimer’s disease=Alzheimer’s disease and other 
dementias. Other cardiovascular=other cardiovascular and circulatory diseases. Cirrhosis hepatitis C=cirrhosis of the liver secondary to hepatitis C. Brain cancer=brain and central nervous system cancer.
771 385 355 190 237 247 255 279 182 142 105 127 97·8 177 124 156 194 45·8 101 69 119 70·6 89·4 104 59·6
710 376 396 207 270 287 267 284 194 140 106 122 99·4 177 129 170 148 57·1 107 65·3 133 74·4 90·4 107 56·7
782 389 395 186 257 257 277 280 215 141 113 123 114 178 125 197 155 53 127 78·1 130 75·4 90·2 112 72
832 394 394 213 242 272 281 300 190 128 98 118 120 224 144 249 187 66·8 95·3 76·7 144 78·3 87·7 108 50·4
882 454 421 199 196 277 262 289 150 135 103 124 103 269 153 193 168 73·5 101 99·8 130 60·5 81·9 115 72·1
919 417 492 228 239 289 275 291 190 136 107 128 117 230 161 219 129 57 106 77 130 70·1 89·3 123 44·5
792 363 415 202 228 248 263 307 205 146 135 114 264 160 217 177 76·7 101 88·1 151 72·1 100 117 85·4
851 459 412 263 265 293 286 297 225 149 137 128 125 181 147 220 167 69·5 106 74·8 140 84·2 102 110 78·1
887 435 465 221 218 319 279 266 204 126 122 124 138 224 158 203 194 75·3 107 81·3 129 76·5 95·4 99·2 73·4
832 435 394 217 299 340 257 278 195 148 105 126 95 194 163 159 126 57·2 134 75·8 132 77·6 95·5 143 77·6
922 460 430 234 301 298 278 301 181 138 121 141 108 250 134 232 188 55·9 108 74·8 132 90·3 97·9 101 77·8
859 438 457 234 294 293 292 303 246 146 129 137 128 198 130 237 214 71·5 114 79·5 134 73 106 108 77·5
926 479 416 261 289 352 270 305 154 149 127 122 110 204 128 151 174 77·4 120 83·5 147 88·2 96·6 114 67·1
958 572 480 260 258 306 277 280 194 148 127 120 107 212 170 191 162 88·3 99·3 113 129 89·3 72·7 94·7 112
988 472 460 277 253 318 294 304 203 144 129 129 138 260 144 235 196 79·4 112 91·6 122 76·8 112 110 63·6
1050 540 495 298 255 319 295 298 217 138 122 120 127 201 166 212 199 67·8 104 102 138 81·9 95·7 106 108
1043 514 525 296 235 351 281 294 233 139 139 119 149 277 128 191 167 87 110 101 129 83·7 95·1 112 80
968 451 546 256 289 338 309 299 217 146 117 130 142 206 152 244 244 90·7 107 93·7 121 86·6 103 116 47·8
1007 531 446 314 311 383 261 291 239 150 131 117 115 220 144 144 222 104 122 94·3 112 76·2 88·1 112 115
982 566 469 332 301 326 296 316 243 165 151 121 144 251 133 175 209 106 116 84·6 127 95·9 107 109 104
1000 503 473 292 273 299 302 305 302 152 139 133 139 264 160 221 248 102 127 81·6 133 96 107 115 127
1066 567 465 300 311 326 313 298 229 162 150 137 129 254 147 212 241 89·2 105 98·2 126 98·6 125 112 118
1122 623 497 367 289 343 305 295 254 154 143 127 138 254 147 193 251 122 113 99·7 125 89·7 100 112 140
1260 742 488 362 265 339 317 280 277 131 140 113 135 274 136 141 107 132 105 118 117 92·9 119 103 90·8
1158 604 551 359 313 372 306 309 240 161 144 127 151 260 158 274 287 105 122 106 118 91·2 106 127 103
1189 687 467 434 331 367 279 279 255 152 156 124 117 236 146 163 255 150 120 101 116 91·1 93·5 119 134
1230 629 563 371 281 353 321 305 272 147 141 123 128 260 169 217 262 94·2 96·9 117 154 81·4 94·2 140 103
1127 561 566 342 323 369 311 294 248 146 141 131 147 329 173 244 275 115 107 110 133 83·2 116 127 134
1165 665 507 392 294 322 331 297 288 162 165 131 162 222 140 207 249 142 113 89·6 140 99 87·3 133 214
1159 725 465 452 300 340 328 286 256 175 175 127 158 249 155 146 257 149 118 100 122 106 103 104 204
1189 643 579 361 286 397 335 281 266 156 150 128 152 280 163 200 223 131 103 108 144 91·8 103 138 121
1279 712 500 412 294 367 346 331 303 158 158 128 154 235 157 201 327 122 114 104 114 113 109 106 174
1377 812 525 553 365 377 308 263 240 173 182 130 133 267 147 150 295 181 119 118 100 102 76·8 105 180
1334 748 567 481 293 406 352 305 275 157 146 134 169 317 175 224 367 166 119 125 105 84·9 117 121 129
1368 781 560 474 332 387 349 298 263 162 158 126 157 274 162 200 360 155 118 125 121 96·9 116 125 139
1433 874 589 526 303 407 304 287 290 167 161 134 162 259 163 204 267 134 117 129 120 98·2 113 137 184
1477 982 677 548 311 392 396 315 328 175 159 140 150 187 189 205 205 167 114 137 120 110 104 121 181
1520 850 647 569 364 439 335 313 330 166 174 128 191 253 158 224 327 188 120 124 108 112 103 105 202
1449 961 516 623 286 362 337 291 362 179 196 127 183 242 140 190 241 234 136 91·4 111 139 128 105 314
1658 916 521 517 296 384 321 306 402 197 193 133 164 334 146 192 286 201 145 115 114 125 101 100 301
1634 917 610 653 305 415 355 307 275 179 164 118 193 408 148 193 418 232 117 150 109 91 107 103 171
1653 961 600 644 346 429 368 307 304 185 211 132 169 307 168 229 366 231 126 131 125 115 102 102 230
1481 961 583 616 309 392 386 303 438 198 205 141 183 279 147 137 294 246 128 138 130 107 99·3 92·6 407
1854 1171 638 761 333 473 375 299 346 185 189 122 160 359 150 220 335 204 129 156 113 103 99·4 115 280
1818 1318 723 753 372 443 408 324 399 198 182 131 169 236 141 154 237 275 112 170 119 129 110 114 315
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presents the results of the ANOVA analysis by year for 
various measures in this group. For men in 2013, at least 
85% of variation was associated with IMD-2010 score, 
and less than 10% was associated with English region for 
all measures, whereas for women the values explained 
by level of deprivation of the area were slightly lower, 
especially for mortality.
Change across all deprivation areas was dominated by 
decreases in cardiovascular diseases and cancers. 
Increased death rates from cirrhosis of the liver, mental 
and substance use disorders, and neurological diseases, 
which were largest in the most deprived areas, reduced 
the progress that would otherwise have been achieved 
from reductions in other causes.
Figure 1 shows the leading causes of YLLs using broad 
disease categories (level 3 in the GBD cause hierarchy). 
The leading causes of death overall are shown in the 
appendix (p 1). Ranking is based on the number of YLLs 
from each cause, which is a function of age-speciﬁ c rates 
and the distribution of the population by age and sex in 
1990 and 2013. Changes in the number of YLLs and the 
age-standardised YLL rate are shown to highlight the 
eﬀ ect of demographic change on numbers of YLLs (eg, 
YLLs due to Alzheimer’s disease and other dementias 
have increased by 31% despite a 3% decline in the 
age-standardised rate). The top four causes of death in 
1990 (ischaemic heart disease, cerebrovascular disease, 
lung cancer, and chronic obstructive pulmonary disease 
[COPD]) remain at the top in 2013, despite substantial 
declines in their age-standardised rates. Lung cancer and 
cerebrovascular disease switched ranks because of the 
large change in cerebrovascular disease age-standardised 
rates (−55%, 95% UI –59 to −50) between 1990 and 2013. 
Alzheimer’s disease and other dementias increased in 
rank (from eighth to ﬁ fth) even though there was a 
statistically non-signiﬁ cant decline in age-standardised 
rates; this needs to be considered in view of an increase 
in the recording of Alzheimer’s disease on death 
certiﬁ cates.29 Lower respiratory infections, colorectal 
cancer, breast cancer, and self-harm all remained highly 
ranked but still showed reductions in age-standardised 
YLL rates of more than 34% and a reduction in numbers 
of YLLs. Large reductions in both numbers and rates of 
YLLs were also observed for preterm birth, road injuries, 
aortic aneurysm, and diabetes. By contrast, as for 
Alzheimer’s disease and other dementias, YLL numbers 
for several other cancer types increased even though 
age-standardised rates declined slightly. There were 
increases in both numbers and rates for only a small 
number of causes, notably cirrhosis of the liver due to 
hepatitis C and drug use disorders.
Figure 2 shows age-standardised YLL rates for both sexes 
from GBD level 3 causes in England and its nine regions 
relative to the EU15+ countries. Across the EU15+ 
countries, the absolute and relative ranges in 
age-standardised rates for diﬀ erent causes are markedly 
diﬀ erent. Within the EU15+ countries, the ratio of 
maximum rate to minimum rate is less than 2·0 for eight 
Figure 4: The 25 leading GBD level 3 causes of disability-adjusted life years (DALYs) in England, both sexes combined, 1990, 2005, and 2013, with age-standardised median percent change
Ranks are based on the number of DALYs. 95% UIs for mean rank are from 1000 draws of DALYs. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.
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of the top 25 causes: leukaemia, ovarian cancer, brain 
cancer, other neoplasms, pancreatic cancer, breast cancer, 
colorectal cancer, and lung cancer. Ratios of maximum-to-
minimum rate greater than 4·0 are seen for drug use 
disorders (10·4), oesophageal cancer (5·8), lower respiratory 
infections (4·2), neonatal preterm birth (4·5), self-harm 
(5·3), and stomach cancer (4·1). Across English regions, 
the only cause with a ratio of maximum-to-minimum rate 
greater than 2·0 is cirrhosis of the liver due to hepatitis C 
(2·3). Eight other disorders have a ratio between 1·5 and 
2·0: ischaemic heart disease, lung cancer, COPD, 
congenital abnormalities, road injuries, neonatal preterm 
birth, stomach cancer, and drug use disorders. For some 
causes, such as lower respiratory infections and breast 
cancer, all English regions are signiﬁ cantly above the 
international mean, indicating that England is 
performing poorly for these disorders. For self-harm and 
road injuries, the opposite is true with all English regions 
being signiﬁ cantly below the mean.
Figure 3 is a comparison of age-standardised YLL rates 
for causes within each deprivation area with the England 
rate in 2013. Some causes such as ischaemic heart 
disease or COPD are largely ordered following the overall 
age-standardised YLL rate, whereas other causes have 
distinct patterns. Breast cancer and prostate cancer show 
much less variation across the deprivation areas. Other 
neoplasms and road injuries have variable patterns: in 
some regions, deprivation level 5 (least deprived) has 
higher rates than deprivation level 1 (most deprived) in 
other regions. Lymphoma, leukaemia, and brain cancer 
have distinctive patterns that do not follow levels of 
deprivation. The ratio of maximum age-standardised YLL 
rate to minimum age-standardised YLL rate across 
deprivation areas as a measure of relative inequality 
ranges from 1·3 (low) for prostate cancer to 9·2 (high) 
for drug use disorders. Other examples of high ratios 
include COPD (4·4), and cirrhosis from hepatitis C (7·1). 
In 2013, 91·1% of the variance in YLLs for men is 
explained by deprivation area and only 5·1% by region 
(table 1); for women, 78·7% of the variance is explained 
by deprivation area and 11·7% by region (table 1).
Levels of YLDs from 1990 to 2013 have changed much 
less than YLLs for England (appendix p 21). Figure 4 
provides the overall assessment of trends in DALYs using 
level 3 of the GBD cause hierarchy from 1990 to 2013. 
The leading cause of DALYs in 2013 is low back and neck 
pain. Sense organ diseases, consisting of hearing loss 
and vision loss, and depressive disorders are leading 
causes of DALYs although they do not cause substantial 
YLLs. Other causes such as chronic kidney disease, 
migraine, and eating disorders are important causes of 
YLDs and DALYs. Other musculoskeletal disorders, 
anxiety disorders, and drug use disorders are also leading 
causes of DALYs. Age-standardised DALY rates by 
deprivation areas for the leading causes of DALYs are 
provided in the appendix (p 2). Some causes, such as 
depressive disorders, show substantial variation among 
deprivation areas across English regions. For many 
causes that predominantly lead to YLDs, UIs are large 
such that nearly all deprivation areas have levels that are 
not signiﬁ cantly diﬀ erent from the England mean.
DALY trends are a composite of trends in YLLs and 
YLDs; trends that in some cases, might be going in 
opposite directions. Examples of disorders for which 
YLL and YLD rates are changing in diﬀ erent directions, 
or where all measures are increasing markedly, can be 
seen in table 2. For instance, age-standardised YLL rates 
for prostate cancer signiﬁ cantly declined by 20·9% 
(95% UI 6·46–31·37), whereas YLD rates signiﬁ cantly 
increased by 42·6% (2·52–72·19). Such examples show 
that only summary measures combining morbidity, 
mortality, and disability data provide a comprehensive 
understanding of the eﬀ ect of a disorder on a population.
Estimates for deaths, YLLs, YLD, and DALYs in England 
in 1990 and 2013 for all ages and age-standardised rates 
are provided in the appendix (pp 23–40).
Overall for England in 2013, all identiﬁ ed risk factors 
jointly explain 39·6% (95% UI 37·7–41·7) of DALYs, with 
the remaining 60∙4% DALYs as yet unexplained by the 
risk factors analysed (ﬁ gure 5). Risk factors together 
explain 83·9% (81·6–86·2) of cardiovascular disease 
DALYs, 46·7% (44·5–49·3) of neoplasm DALYs, 49·7% 
Deaths YLLs YLDs DALYs Total burden of DALYs 2013
Cerebrovascular disease –46·2% (–50·65 to –37·93)* –54·9% (–59·01 to –49·67)* 14·2% (7·89 to 20·12)* –49·8% (–54·40 to –44·69)* 535 900 (475 100 to 607 000)
Chronic obstructive 
pulmonary disease
–19·3% (–27·43 to –2·76)* –32·4% (–39·25 to –21·41)* –0·9% (–12·25 to 10·28) –21·9% (–28·42 to –15·25)* 527 200 (448 800 to 620 400)
Alzheimer’s disease and 
other dementias
6·9% (–6·42 to 20·11) –3·4% (–14·31 to 6·87) 0·2% (–11·40 to 10·40) –2·2% (–11·61 to 5·78) 463 400 (412 800 to 514 600)
Diabetes –50·4% (–53·89 to –46·91)* –55·8% (–58·66 to –52·73)* 75·3% (56·88 to 94·11)* 20·1% (5·51 to 34·98)* 360 200 (262 900 to 468 900)
Prostate cancer† –16·2% (–44·83 to 0·52) –20·9% (–51·37 to –6·46)* 42·6% (2·52 to 72·19)* –14·2% (–45·70 to 1·21) 138 100 (93 300 to 186 200)
Liver cancer 56·6% (11·83 to 87·65)* 41·0% (6·19 to 66·01)* 72·3% (18·86 to 126·55)* 41·4% (6·34 to 66·45)* 49 400 (37 500 to 57 200)
Cirrhosis of the liver 41·7% (31·71 to 51·08)* 50·8% (40·64 to 61·31)* 26·2% (20·17 to 32·34)* 50·0% (40·15 to 60·25)* 181 000 (169 000 to 192 500)
Drug use disorders 113·5% (6·99 to 143·31)* 107·7% (4·07 to 137·47)* –4·9% (–9·68 to 0·19) 18·2% (–1·56 to 28·47) 201 200 (157 300 to 246 500)
Data are percent change (95% UI). YLLs=years of life lost. YLDs=years lived with disability. DALYs=disability-adjusted life-years. *Statistically signiﬁ cant. †Men only. 
Table 2: Change in age-standardised rates (per 100 000) of death, YLLs, YLDs, and DALYs for both sexes from 1990 to 2013 for select disorders in England and total DALYs in 2013
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Metabolic and environmental 
% of attributed burden: 
0·8% (111 641 DALYs) 
% of total burden: 
0·3% (44 198 DALYs) 
Metabolic
% of attributed burden: 
23·6% (3 222 023 DALYs) 
% of total burden: 
9·3% (1 275 599 DALYs) 
Behavioural and metabolic
% of attributed burden: 
22·3% (3 048 860 DALYs) 
% of total burden: 
8·8% (1 207 043 DALYs) 
Behavioural and 
metabolic
% of attributed 
burden: 
6·4% (148 860 DALYs) 
% of total burden: 
3·0% (69 572 DALYs) 
Behavioural and metabolic
% of attributed burden: 
7·2% (59 931 DALYs) 
% of total burden: 
3·6% (29 797 DALYs) 
Behavioural and 
metabolic
% of attributed burden: 
50·6% (1 048 437 DALYs) 
% of total burden: 
42·4 % (880 014 DALYs) 
Metabolic and environmental 
% of attributed burden: 
1·4% (29 224 DALYs) 
% of total burden: 
1·2% (24 530 DALYs) 
Metabolic and environmental 
% of attributed burden: 
1·5% (12 857 DALYs) 
% of total burden: 
0·8% (6392 DALYs) 
Environmental 
% of attributed burden: 
5·2% (714 085 DALYs) 
% of total burden: 
2·1% (282 706 DALYs) 
Environmental 
% of attributed burden: 
4·8% (113 360 DALYs) 
% of total burden: 
2·3% (52 980 DALYs) 
Environmental 
% of attributed burden: 
0·8% (16 057 DALYs) 
% of total burden: 
0·7% (13 478 DALYs) 
Environmental 
% of attributed burden: 
10·4% (86 704 DALYs) 
% of total burden: 
5·2% (43 107 DALYs) 
Behavioural 
% of attributed burden: 
42·3% (5 794 255 DALYs) 
% of total burden: 
16·8% (2 293 942 DALYs) 
Behavioural 
% of attributed burden: 
66·9% (1 565 108 DALYs) 
% of total burden: 
31·3% (731 474 DALYs) 
Behavioural 
% of attributed burden: 
34·2% (285 624 DALYs) 
% of total burden: 
17·0% (142 006 DALYs) 
Behavioural and 
environmental 
% of attributed burden: 
4·2% (570 300 DALYs) 
% of total burden: 
1·7% (225 781 DALYs) 
A All causes B Cardiovascular diseases
C Neoplasms D Injuries
Behavioural 
% of attributed burden: 
14·7% (305 705 DALYs) 
% of total burden: 
12·4% (256 596 DALYs) 
Behavioural and 
environmental 
% of attributed burden: 
1·3% (26 260 DALYs) 
% of total burden: 
1·1% (22 041 DALYs) 
Metabolic
% of attributed burden: 
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Figure 5: Proportion of all-cause DALYs (A), cardiovascular disease DALYs (B), neoplasm DALYs (C), and injury DALYs (D) attributable to behavioural, environmental and occupational, and 
metabolic risk factors and their overlaps for all ages in 2013
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Figure 6: Disability-adjusted life-years (DALYs) attributed to level 2 risk factors in 2013 in England for both sexes combined (A), men (B), and women (C)
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(46·5–52·6) of injury DALYs, 62·0% (57·9–65·9) of 
chronic respiratory disease DALYs, but only 1·9% 
(1·4–2·4) of neurological disease DALYs (ﬁ gure 5; DALYs 
attributable to risk factors for chronic respiratory disease 
and neurological disease are not presented; for DALYs 
attributable to all risk factors, see appendix p 41).
Behavioural risks account for 28·0% (95% UI 
25·6–30·3) of DALYs, metabolic risks for 19·2% 
(18·0–20·5), and environmental and occupational risks 
for 4·7% (4·3–5·2). Almost half of DALYs due to 
metabolic risks overlap with behavioural risks, which is 
particularly large for cardiovascular disease. Behavioural 
risks (particularly tobacco and dietary risks) are the 
greatest contributor to cancer with more modest 
contributions from metabolic risks and environmental 
and occupational risks. Low bone mineral density and 
alcohol consumption are the dominant metabolic and 
behavioural risks, respectively, for injuries (ﬁ gure 5).
The largest contributor to DALYs are dietary risks 
(10·8%, 95% UI 9·1–12·7), an aggregate in the second tier 
of the GBD risk hierarchy of low fruit consumption, low 
vegetables consumption, low whole-grains consumption, 
low nuts and seeds consumption, low milk consumption, 
high red meat consumption, high processed meat 
consumption, high sugar-sweetened beverages con-
sumption, low ﬁ bre consumption, suboptimal calcium 
intake, low seafood omega-3 fatty acids consumption, low 
polyunsaturated fatty acids consumptions, high trans fats 
intake, and high sodium intake, closely followed by 
tobacco (10·7%, 9·4–12·0) (ﬁ gure 6).
The rates of DALYs attributed to each of the three major 
risk categories have declined between 1990 and 2013: by 
28·3% (95% UI 25·0–31·5) for metabolic risks, by 
23·7% (21·5–26·0) for behavioural risks, and by 28·8% 
(23·7–35·0) for environmental and occupational risks 
(data not shown). Declines are due to reductions in DALY 
rates attributable to most risk factors: between 1990 and 
2013, DALY rates signiﬁ cantly declined for 11 of the 
15 largest risks at tier 3 in the risk hierarchy (tobacco, 
high blood pressure, cholesterol, low glomerular ﬁ ltration 
rate, low physical activity, diet low in fruit, vegetables, 
nuts, and seeds, diet high in sodium and processed meat, 
and air pollution), but remained unchanged for high 
body-mass index (BMI), high fasting plasma glucose, and 
alcohol. Illicit drug use is the only top 15 risk for which 
the DALY rates increased signiﬁ cantly. These changes in 
DALY rates attributed to major risks can be caused by a 
change in risk exposure, a change in outcomes associated 
with the risk, or a combination of the two. There was a 
signiﬁ cant decline in exposure to tobacco, high blood 
pressure, cholesterol, and air pollution. Exposure to the 
top dietary risks, physical activity, alcohol use, and low 
glomerular ﬁ ltration rate changed little. Exposure to 
high BMI and high fasting plasma glucose increased 
signiﬁ cantly, but large declines in cardiovascular disease 
outcomes are mainly responsible for the diﬀ erence in 
trends between exposure and attributable burden. Of the 
ten leading tier 2 risks, seven cause a greater proportion 
of total DALYs in men than in women. The exceptions are 
physical inactivity, fasting plasma glucose, and low 
glomerular ﬁ ltration rate, with equal proportions of 
DALYs between men and women (ﬁ gure 6).
The leading risk factors by deprivation level in England 
are shown in the appendix (p 3). There is a consistency of 
rank order of major risk factors: smoking, high BMI, and 
high blood pressure are the leading risks in all deprivation 
areas. Smoking is strongly socially stratiﬁ ed: it ranks 
above high BMI in deprivation level 1 (most deprived) in 
all English regions, but the converse is true in deprivation 
levels 4 and 5 across seven of those nine regions. In 
deprivation level 1 in six regions, alcohol use is the fourth 
leading risk factor, whereas it is high fasting plasma 
glucose for other regions. Drug use is a more highly 
ranked risk factor in most of the more deprived areas 
when compared with less deprived areas.
Discussion
England had better than average outcomes in 2013 when 
compared with EU15+ countries and other countries of 
the UK. Despite sharing the same health and social 
care system, some English regions have outcomes 
commensurate with, or better than, those of the 
best-performing nations among the EU15+ countries, 
whereas others have outcomes worse than any of these 
countries. Life expectancy has increased at all levels of 
deprivation within English regions, but the variation in 
life expectancy within regions has decreased only slightly 
for women and not at all for men.
Routine annual mortality statistics show a year-on-year 
decline in age-standardised mortality rates in England 
and the rest of the UK from 1983 to 2013:30 mortality rates 
in Scotland are known to have been higher than in 
England, whereas mortality rates in Wales and Northern 
Ireland, although higher, have generally been closer to 
those in England. Routine statistics show that the range 
in life expectancy at birth between regions has reduced 
for men in the past 5 years, from 2·7 years to 2·4 years, 
but stayed the same for women, at 2·4 years.31 Our results 
show a larger range in life expectancy between deprivation 
areas, at 8·2 years for men and 6·9 years for women in 
2013, with only a small reduction since 1990 for 
women and none for men. Routine mortality statistics 
undiﬀ erentiated by deprivation thus mask substantial 
inequalities within English regions (ﬁ gure appendix 2). 
Consistent with other analyses,32–35 geography accounted 
for only a small proportion of the variance between 
deprivation areas (table 1). At the district level, populations 
are more homogeneous, and inequalities in mortality 
rates more evident. District-level data reported by Bennett 
and colleagues36 suggest inequalities at this level are 
increasing. Inequality within regions is therefore greater 
than it is between them, and it is therefore important to 
address the problems caused by deprivation wherever 
they occur and in all regions of the country.
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Many of the most common causes of DALYs show 
striking variation by deprivation area (appendix p 2); as 
for mortality, this inequality largely follows patterns 
determined by level of deprivation, not geography. For 
low-mortality disorders, such as musculoskeletal disease, 
DALYs tend to be based on incomplete data at subnational 
level, and the level of inequality for many disorders is 
likely to be underestimated.
The Greater London deprivation groups are an 
exception to the overall pattern of inequality because their 
burden of disease is less than expected for their level of 
deprivation (see ﬁ gure appendix 2 and appendix p 2). 
Possible explanations include artifact due to the method 
of measuring deprivation, ethnic composition of the 
population, healthy migrant eﬀ ect, and diﬀ erential 
selective migration within England.37 London has also 
received more health investment than other English 
regions. The eﬀ ect of health-care spending on the outputs 
from GBD would be a useful next stage of analysis.
Improvements in life expectancy in England, as 
elsewhere, have been driven by decreases in mortality 
from cardiovascular disease and cancers.38 Increasing 
mortality from neurological disorders and cirrhosis of 
the liver have partially oﬀ set these gains. In other 
countries, the negative eﬀ ect of liver disease has been 
much less marked (see France, Spain, Sweden, and Italy 
in ﬁ gure appendix 2). This rising burden of liver disease 
in England requires both a policy and health-care 
response.39 Among the other leading causes of premature 
death, Alzheimer’s disease and other dementias are 
increasingly important, although age-speciﬁ c death rates 
have declined slightly, consistent with a decline observed 
in serial prevalence surveys.21,40–42
Signiﬁ cant diﬀ erences in YLL rates by country for 
speciﬁ c causes (ﬁ gure 2) include various cancers. 
International and subnational diﬀ erences in mortality 
are likely to be strongly driven by diﬀ erences in incidence 
as well as in survival (eg, for lung cancer). Any national 
strategy for cancer needs to address primary prevention 
as well as eﬀ ective care for people with cancer.
Musculoskeletal disorders are a dominant cause of 
YLDs, and consume a substantial amount of 
health-system resources. These disorders are strongly 
age-related and will become increasingly prevalent as the 
population ages.43 Another major contributor to YLDs are 
depressive and anxiety disorders, the rates of which have 
not declined. Given the epidemiological assessment of 
relative burden, services for these disorders rarely receive 
the attention they deserve. This relative neglect is 
beginning to change with calls for parity of esteem for 
mental and physical health. Opportunities to improve 
management of anxiety and depression in primary care 
exist;44–46 evidence suggests that prevention aimed at 
high-risk groups before depression arises is eﬀ ective.47
For several disorders, although mortality rates may have 
reduced, the burden of ill health has either not declined by 
the same extent or is increasing. In England, and in other 
high-income countries, a larger share of DALYs now comes 
from YLDs, rather than YLLs. For example, in 
cerebrovascular disease and diabetes, YLLs have decreased, 
but YLDs have increased signiﬁ cantly; for COPD, YLLs 
have decreased signiﬁ cantly but with almost no change in 
YLDs. Whereas mortality rates from cardiovascular 
complications of diabetes have fallen, the prevalence of 
people living with diabetes is rising. Data from the National 
Diabetes Audit show that 36·0% of people with diagnosed 
diabetes living in England are estimated to have had their 
HbA1c, blood pressure, and cholesterol values treated to 
target in 2012–13.48 These data together indicate a high 
level of unmet need for prevention of the consequences of 
diabetes and for the active management of long-term 
disorders in general.
In some cases, the increasing relative contribution of 
YLDs might be the eﬀ ect of improved survival (eg, from 
stroke and some cancers), leading to higher prevalence 
and many people living with disorders that previously 
would have proved fatal. Survivors will also be at risk 
of developing other disorders, particularly disorders 
associated with ageing, leading to steadily increasing 
lifetime risks of some cancers and of musculoskeletal 
disease, for example. One consequence of the growing 
phenomenon of survivorship, together with the eﬀ ect of 
population ageing, will be much higher numbers of 
patients with multimorbidity than in the past.
A major strength of the GBD study is the ability to 
estimate the contribution of diﬀ erent causal factors to the 
burden of mortality and morbidity and, by implication, 
the extent to which that burden could be reduced by 
modifying those risks. GBD 2013 was developed to 
increase understanding of the individual and overlapping 
eﬀ ects of diﬀ erent risk factors, generating outputs that 
are more informative to formulate preventive strategies. 
The overall proportion of preventable burden reduced 
between 1990 and 2013 because of the decline in the 
incidence of the more preventable diseases (ischaemic 
heart disease and some cancers) and a relative increase in 
other diseases with an apparently lower potential for 
prevention (neurological disorders, and Alzheimer’s 
disease and other dementias).
Important metabolic risks, including high blood 
pressure, high fasting plasma glucose, low glomerular 
ﬁ ltration rate, and high cholesterol, overlap signiﬁ cantly 
with modiﬁ able behavioural risk factors, such as diet and 
physical activity; for example, mean systolic blood pressure 
in the UK has fallen by over 3 mm Hg in the last decade, 
mainly as a result of reduced dietary salt intake.49,50 
In general, behavioural risk factors make a greater 
contribution to DALYs (28%) than metabolic risks (19%) 
or environmental and occupational risks (5%). The relative 
contribution of individual risks and type of risk will vary 
by disorder. Environmental risks, such as air pollution, 
albeit smaller than the other two risk categories, remain 
quantitatively important and require speciﬁ c consideration 
within national and local public health policy and strategy.
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The combination of unhealthy diets, physical inactivity, 
and high BMI is the biggest overall contributor to DALYs. 
Tobacco smoking remains a leading attributable risk 
factor for DALYs in England, and is notably still the 
leading risk factor for women. In line with this, mortality 
from lung cancer for men declined by 24% between 
1990 and 2013 but did not change signiﬁ cantly for women. 
The peak eﬀ ect of smoking in women is probably only 
now being reached in England.38
Alcohol consumption is the third leading behavioural 
risk factor overall but is the leading behavioural cause of 
injury. In GBD 2013, only about a third of deaths from 
cirrhosis could categorically be assigned to alcohol as the 
underlying cause (cirrhosis due to alcohol accounts for 
only 29·4% of DALYs due to cirrhosis; appendix p 36); 
however, alcohol also contributes to cirrhosis where it is 
not the underlying cause. In the risk factor analysis, 
therefore, the proportion of cirrhosis of the liver DALYs 
attributed to alcohol in England was 69·5% in 2013. This 
estimate is comparable to ﬁ ndings of another study39 that 
showed 75% of cirrhosis of the liver to be attributable to 
alcohol. Improved data on cirrhosis of the liver and liver 
cancer by aetiology are needed, including a better 
assessment of the role of obesity as a cause of fatty liver 
disease.51–55 The contributions of various aetiologies to 
cirrhosis of the liver will probably vary geographically 
across England.
Most, if not all, behavioural, metabolic, and environ-
mental and occupational risks are strongly related to the 
socioeconomic determinants of health, which need to be 
addressed in any credible public health strategy.56 In 
future rounds of the GBD study, we plan to quantify 
socioeconomic determinants of health more directly.
This study has several important limitations beyond 
those applying more generally to GBD studies and 
reported elsewhere.
First, the level of aggregation of causes aﬀ ects their 
relative ranking (eg, splitting cirrhosis of the liver by 
cause aﬀ ects where the individual causes appear in the 
rankings). The online data visualisations associated with 
this study allow the user to interrogate the results using 
diﬀ erent levels of the GBD cause hierarchy.
Second, subnational data at the regional level are not 
available for the estimation of prevalence and incidence 
for several diseases. Estimates depend on the GBD 
Bayesian models, borrowing from studies in other 
settings while using covariates as predictors. This 
limitation could be improved by collecting additional 
data on morbidity in the English population. Possible 
approaches include increasing the sample size of the 
Health Survey for England and augmenting the 
inc reased sample size with additional health 
examinations, incorporating data from large primary 
care surveys, such as the Clinical Practice Research 
Datalink, or further use of linked primary and secondary 
care datasets. These estimates might be aﬀ ected by 
supply and access factors.
Third, we assigned each lower super output area on the 
basis of the level of deprivation in 2010 and used this 
assignment for the analysis in all time periods. As some 
of the lower super output areas may have changed their 
relative level of deprivation during the period, we might 
have underestimated some of the inequalities related to 
deprivation in 1990. Any reductions in inequality would 
probably be underestimated because of this approach. 
Such errors could be assessed by reference to longitudinal 
studies such as the ONS Longitudinal Study. Furthermore, 
deprivation is measured at the time that disease outcome 
is recorded, whereas the contribution of deprivation is 
relevant across the lifecourse. The estimation of the 
relation between deprivation and disease does not account 
for this, thereby potentially underestimating its eﬀ ect in 
some areas and overestimating it in others.
Fourth, in view of the limited data by deprivation level 
for some causes that do not aﬀ ect mortality, inequality 
across deprivation levels might be substantially under-
estimated in the analysis of YLDs.
Fifth, the current GBD method for risk factor attribution 
uses data on exposure to single risk factors and its eﬀ ect 
on each outcome, whereas aggregated eﬀ ects of risk 
factors are made on the basis of assumptions of additive, 
multiplicative, or mediated eﬀ ects and not on the direct 
measurement of exposure to combined risk factors and 
the combined eﬀ ect on outcomes.
Finally, in some analyses, comparisons are made 
between English regions and other countries. Although 
some English regions are similar in size to several of the 
countries in the EU, the potential for diﬀ erential migration 
between English regions is greater than between countries; 
such comparisons are not straightforward.
Some limitations are speciﬁ c to certain disorders. The 
comparative risk assessment, based on the criterion of 
convincing or probable evidence, did not identify any 
modiﬁ able risk factors for Alzheimer’s disease and other 
dementias as suitable targets for public health action. 
Some studies suggest that modiﬁ able behavioural risks 
do exist,57–62 but more research is needed to determine 
whether these ﬁ ndings would meet the criterion for 
inclusion in the GBD framework. In future rounds of 
GBD, we intend to make separate estimates for 
Alzheimer’s disease and vascular dementia and will 
assess the evidence for the eﬀ ect of some metabolic and 
behavioural risk factors on vascular dementia in 
particular. In the GBD 2013 framework, dementia in 
Parkinson’s disease or in stroke is considered in the 
respective disease categories rather than in the 
Alzheimer’s and other dementias category.
We estimate that about 3600 deaths were attributable to 
self-harm in England in 2013. This diﬀ ers from oﬃ  cial 
ﬁ gures released by the Oﬃ  ce for National Statistics, 
which indicate 4722 suicides in England in 2013.63 This 
diﬀ erence is due to the partial redistribution in the GBD 
study of ICD-10 mortality codes for injury and poisoning 
of undetermined intent (ICD-10 codes Y10–Y34) to 
For the ONS Longitudinal Study 
see http://www.ons.gov.uk/ons/
guide-method/user-guidance/
longitudinal-study/index.html
For the IHME online data 
visualisations see http://vizhub.
healthdata.org/gbd-compare/
england
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suicide as opposed to all these codes being counted as 
suicide by the Oﬃ  ce for National Statistics; our estimates 
will therefore underestimate the overall suicide burden 
in England compared with oﬃ  cial ﬁ gures. Furthermore, 
when we estimated the attributable risk for mental and 
substance use disorders and self-harm, social risk factors 
(for example, divorce, low income, debt and job loss) 
were not included and therefore not attributed.
The contribution of diet components other than 
sugar-sweetened beverages to BMI has not been included 
in this analysis; therefore, the full consequences of diet 
might be greater than the eﬀ ect shown in these results.
No comprehensive picture has been made of the level 
and distribution of the burden of disease in England, 
despite the fact that health policy is now devolved to 
individual countries within the UK. The outputs of such a 
framework can help test whether the eﬀ ort being expended 
on a particular disease or risk factor is proportionate to 
burden or attributable risk, respectively. Our results 
therefore have implications for national government, local 
government, and health services in England.
For national government, the quantiﬁ cation by the 
GBD study of the continuing burden of preventable ill 
health more than justiﬁ es recent calls for a “radical 
upgrade in prevention and public health”.3 National 
government will also be concerned that improvements in 
premature mortality in England are diminished by 
increases in deaths from liver disease, by contrast with 
the declines seen in similar countries such as France.
For English local authorities in their new role as leaders 
for local population health, the most striking ﬁ ndings 
relate to inequalities, not only the size and nature of the 
eﬀ ect of deprivation on health but also that the gap 
between the most deprived and least deprived areas of 
England shows little sign of reducing. The GBD 2013 
results underline the fact that local authorities in the 
more disadvantaged regions of England are not the only 
ones that need to tackle the eﬀ ects of deprivation, and to 
make this task a priority.
For health services, one important implication of our 
results is the scale of the increasing level of disability 
and, especially, the growth of multimorbidity. This new 
form of demand requires new and more integrated 
models of care spanning health and social services that 
respond to the speciﬁ c needs and circumstances of 
individual patients. The other important implication for 
health services is that about 40% of their workload is 
potentially preventable, yet the proportion of health 
expenditure directed at prevention, although hard to 
estimate reliably, is probably closer to 4%.64
Combining GBD results with data on expected trends 
in population structure and risk factors could be used to 
anticipate future disease burden and thereby provide an 
important input to economic models and forecasts. This 
will be addressed in future GBD work. The importance of 
prevention argues for robust, standardised, comparative 
assessments of the cost-eﬀ ectiveness of diﬀ erent public 
For NICE’s 2013 guide to 
technology appraisal see http://
www.nice.org.uk/article/pmg9/
chapter/foreword
health policies to aid decision making, akin to those used 
in England for health technologies. Such assessments are 
likely to highlight the need for more empirical evidence 
of the eﬀ ectiveness of speciﬁ c preventive approaches. 
Finally, there are substantial gaps in routine and survey 
data on the prevalence of morbidity at the subnational 
level that could be addressed.
If the levels of health seen in the best performing 
English regions could be achieved in the worst 
performing regions, England would have a level of 
overall burden of disease as low as any country with a 
developed post-industrial economy. This interpretation 
provides a strong argument for implementing policies 
for eﬀ ective prevention and treatment, but these policies 
must also be designed to reduce inequalities associated 
with the socioeconomic determinants of health.
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